Ebola Virus Disease

8
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
375%
Small Molecule
125%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
3 programs
1
2
BioNTech - Pfizer COVID-19 vaccinePhase 4Vaccine1 trial
rVSVDG-ZEBOV-GP Ebola Virus VaccinePhase 4Vaccine1 trial
Recombinant Vesicular Stomatitis Vaccine for EbolaPhase 2Vaccine1 trial
Active Trials
NCT06100913Active Not Recruiting30Est. Aug 2027
NCT06587503Not Yet Recruiting72Est. May 2025
NCT05992480Recruiting40Est. May 2026
Alliance Pharmaceuticals
2 programs
1
1
ErveboPhase 31 trial
ErveboPhase 21 trial
Active Trials
NCT05202288Not Yet Recruiting132Est. Aug 2027
NCT06841614Not Yet Recruiting160Est. Aug 2028
Sierra Sciences
1 program
1
ErveboPhase 3
Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
ErveboPhase 2
REGN3470-3471-3479N/A1 trial
Active Trials
NCT03576690Available
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
BrincidofovirPhase 2Small Molecule1 trial
Active Trials
NCT04268966Withdrawn0Est. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Merck & Co.rVSVDG-ZEBOV-GP Ebola Virus Vaccine
Merck & Co.BioNTech - Pfizer COVID-19 vaccine
Alliance PharmaceuticalsErvebo
Alliance PharmaceuticalsErvebo
Merck & Co.Recombinant Vesicular Stomatitis Vaccine for Ebola
Jazz PharmaceuticalsBrincidofovir

Clinical Trials (7)

Total enrollment: 434 patients across 7 trials

NCT05992480Merck & Co.rVSVDG-ZEBOV-GP Ebola Virus Vaccine

REVIVE (Response to the Ebola Virus Vaccine)

Start: Dec 2025Est. completion: May 202640 patients
Phase 4Recruiting
NCT06587503Merck & Co.BioNTech - Pfizer COVID-19 vaccine

Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

Start: Oct 2024Est. completion: May 202572 patients
Phase 4Not Yet Recruiting
NCT06841614Alliance PharmaceuticalsErvebo

EBOla Post-Exposure Prophylaxis

Start: Sep 2026Est. completion: Aug 2028160 patients
Phase 3Not Yet Recruiting
NCT05202288Alliance PharmaceuticalsErvebo

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Start: Jan 2027Est. completion: Aug 2027132 patients
Phase 2Not Yet Recruiting
NCT06100913Merck & Co.Recombinant Vesicular Stomatitis Vaccine for Ebola

Immunology of Ebola Vaccine

Start: Aug 2024Est. completion: Aug 202730 patients
Phase 2Active Not Recruiting
NCT04268966Jazz PharmaceuticalsBrincidofovir

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Start: Oct 2014Est. completion: Dec 20150
Phase 2Withdrawn
NCT03576690RegeneronREGN3470-3471-3479

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

N/AAvailable

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 434 patients
5 companies competing in this space